5th MERIDIANTECH-COVID19 Workshop

Bioelectrical Diagnostics & Coherent Therapy
“COVID-19 Multicentric International Trials for Diagnosis-driven Personalized Precision Therapy”

Saturday 09 May 17:00 Central European Summer Time

Hosted by
MEDPREVENT systems GmbH & Co. KG DE

Spaces limited to 20 participants

To participate in the workshop and further information register at:

madan.thangavelu4@gmail.com

Mobile & WhatsApp: +44 7830 300 728
5th MERIDIANTECH-COVID19 Workshop
Bioelectrical Diagnostics & Coherent Therapy
“COVID-19 Multicentric International Trials for Diagnosis-driven Personalized Precision Therapy"
Saturday 09 May 17:00  CEST – Hosted by MEDPREVENT systems GmbH & Co. KG DE

Past, present and the future of human viral diseases

Vincenzo VALENZI MD (www.cimb.me), Patrizio CARRAI Pisa University (Chemistry), Pasquale AVINO Molise University (Chemistry):
Intermolecule signalling: Subtle molecular signals and their role in regulation of inflammation

Dr. med Michael BAUER, Raimund HOFFMAN & Franziska MICHL: MEDPREVENTsystems GmbH, Marktredwitz, Germany
PROGNOS system and Viral Express: Operating the PROGNOS System and overview of viral testing

Luca GAMBERALE & Milly MORATTI: LEDA/Bicocca Research Center for Innovative Research in Applied Physics, Milan, Italy
Quantum Theory in biology and applications in medicine

Habib DOUAGUI: Professor & Head, Department of Pneumo-allergology, Center Hospitalo Universitaire de Béni Messous, Algiers, Alger
The current state of COVID-19 treatment in Africa: Perspectives and the need for personalized, precision therapy

Judu ILAVARASU: Division of Yoga and Physical Sciences, Swami Vivekananda Yoga Anusandhana Samsthana (SVYASA), Bangalore, India
SVYASA: Priorities for a meridian energy research project in S-VYASA, Bangalore

Vladimir PETRUKHIN: Founder, CardioMood (www.cardiomood.com)
Mobile HRV analysis and expert tools for heart rate analysis for TeleHealth / TeleMedicine

Madan THANGAVELU: www.iiimb.me
PROGNOSNET COVID-19: Organization of the Network, Clinical Studies and Study protocols & Project Timelines
**MERIDIANTECH: COVID 19**

1 **Diagnostics**: Bioelectrical status of meridians and organ function (large intestine and lung meridians)

2 **Diagnostics-driven treatment**: Clinical trials for rebalancing and boosting bioelectrical status & predictive-personalised treatments

---

Stratification of population for grades of health, wellbeing & clinical frailty

<table>
<thead>
<tr>
<th>Age Group</th>
<th>Healthy / Asymptomatic</th>
<th>Pre-symptomatic, Suspected COVID-19</th>
<th>COVID-19 positive</th>
<th>Remission</th>
</tr>
</thead>
<tbody>
<tr>
<td>20-29</td>
<td>Prognos Prophylaxis</td>
<td>Prognos Treat. #1 Antiviral</td>
<td>Prognos Treat.#2</td>
<td>Prognos Boost</td>
</tr>
<tr>
<td>30-39</td>
<td></td>
<td>Prognos Treat. #2 Antiviral + Antiinflammatory</td>
<td>Prognos Treat. #3</td>
<td></td>
</tr>
<tr>
<td>40-49</td>
<td></td>
<td></td>
<td>Prognos Treat. #4</td>
<td></td>
</tr>
<tr>
<td>50-59</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>60-69</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>70+</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

1: Asymptomatic / Healthy: for baseline and grades of health, ages 20 to 70+, males & females

**Prophylaxis**: Bioelectrical status monitoring for personalised dietary & nutritional supplements

2: Pre-symptomatic, symptomatic, suspected COVID-19, requires testing

**Treatment No.1**: Antiviral, gastroprotectant, ??

3: Confirmed COVID-19: Predictive-Personalised Treatment

Stage 1: Initial management outside of critical care **Treatment No. 2**: Antiviral + Antiinflammatory ??

Stage 2: Tending towards critical care (**Treatment No. 3**: ??)

Stage 3: in critical care, (**Treatment No. 4**: ??)

4: **In remission**: Bioelectrical status monitoring for personalised dietary nutritional supplements for rebalancing
NICE UK Critical care referral algorithm to support decision making.

Allegato 1. Percorsi assistenziali e terapeutici per pazienti COVID-19.

TAMPONE EGA TC TORACE VALUTAZIONE FR

ESAMI EMATOCHEMICHI (pannello COVID)

Equisrico
Negatività radiologica
EGA nella norma
Walking-test negativo

Se Paziente positivo per COVID-19 asintomatico o con sintomi lievi (Febbre <37,5°C, tosse, sintomi da raffreddamento senza dispnea, età <70 anni e senza fattori di rischio) TB e TC torace negativo.

Se paziente positivo per COVID-19 con sintomi respiratori lievi ma di età >70 anni e/o con fattori di rischio (BPCO, diabete e cardiopatia) oppure sintomatico o con sintomi lievi (Febbre >37,5°C, tosse, dispnea da lieve a moderata) TB e TC torace con quadro di polmonite:
- Idrossisclorina cp 200 mg, 1x2 oppure x3/die se non disponibile clorochina 500 mg, 1x2/die. Durata della terapia: da 7 a 10 giorni, con timing da stabilire secondo evoluzione clinica (PS: se permanenza prevista oltre le 24 h iniziale trattamento in PS). NB: Necessaria valutazione cardiologica ECG (valutazione QT) 

- Rapido peggioramento clinico: richiedere Remdesivir ad uso compassionevole. Appena disponibile: Remdesivir fiale 150 mg: 1 giorno 200 mg ev in 30 minuti poi 100 mg ev/die per altri 9 giorni in associazione ad idrossisclorina 200 mg, 1x2/die con timing da stabilire secondo evoluzione clinica.

NB: Benché l'attuale evidenza scientifica non supporti l'uso di lopinavir/ritonavir o darunavir/cobicistat 800/150 mg 1 cp/die questi farmaci possono essere considerati nei singoli casi in fase precoce se non disponibile Remdesivir (vedi anche nota AIFA 24/03/20).

- Idrossisclorina cp 200 mg, 1x2 oppure x3/die se non disponibile clorochina 500 mg, 1x2/die. Durata della terapia: da 7 a 10 giorni, con timing da stabilire secondo evoluzione clinica (PS: se permanenza prevista oltre le 24 h iniziale trattamento in PS). NB: Necessaria valutazione cardiologica ECG (valutazione QT) 

Richiedere Remdesivir ad uso compassionevole. Appena disponibile: Remdesivir fiale 150 mg: 1 giorno 200 mg ev in 30 minuti poi 100 mg ev/die per altri 9 giorni in associazione ad idrossisclorina 200 mg, 1x2 oppure x3/die con timing da stabilire secondo evoluzione clinica
+/+Tocilizumab* (richiedere dosaggio IL 6)
+/+Dexametasona 20mg/die per 5 giorni poi a scadere

NB: Benché l'attuale evidenza scientifica non supporti l'uso di lopinavir/ritonavir o darunavir/cobicistat 800/150 mg 1 cp/die questi farmaci possono essere considerati nei singoli casi in fase precoce se non disponibile Remdesivir (vedi anche nota AIFA 24/03/20).

Paziente positivo per COVID-19 con quadro di polmonite grave, ARDS o insufficienza respiratoria globale, scompenso emodinamico, necessità di ricovero in terapia intensiva con assistenza ventilatoria meccanica:
- Idrossisclorina cp 200 mg, 1x2 oppure x3/die via SNG se non disponibile clorochina 500 mg, 1x2/die. Durata della terapia: da 7 a 10 giorni, con timing da stabilire secondo evoluzione clinica (PS: se permanenza prevista oltre le 24 h iniziale trattamento in PS). NB: Necessaria valutazione cardiologica ECG (valutazione QT) 

- Richiedere Remdesivir ad uso compassionevole. Appena disponibile: Remdesivir fiale 150 mg: 1 giorno 200 mg ev in 30 minuti poi 100 mg ev/die per altri 9 giorni in associazione ad idrossisclorina 200 mg, 1x2/die con timing da stabilire secondo evoluzione clinica
+/+Tocilizumab* (richiedere dosaggio IL 6)
+/+Dexametasona 20mg/die per 5 giorni poi a scadere

* Tocilizumab: criteri di inclusione: Termine della fase iniziale di elevata carica virale di COVID-19 (es. apiretroic da >72h e/o trascurabile almeno 7 giorni dall'esordio dei sintomi). Peggioramento degli scambi respiratori tali da richiedere supporto non invasivo o invasivo alla ventilazione (Brescia-COVID respiratory severity scale score ≥2) Elevati livelli di IL-6 (>40 pg/ml) e/o in alternativa elevati livelli di d-dimerico e/o PCT e/o ferritina e/o fibrinogeno in aumento progressivo.

** Se disponibili ed attivi protocolli AIFA: i pazienti verranno valutati per inclusione in studio clinico in via prioritaria.

*** Interventi farmacologici e curazione di farmaci massima attenzione alla possibilità di interazioni farmacocinetiche. In caso di comunque assunzione di altri farmaci utilizzare DRUG PIN: https://acusa.drug-pin.com/app/
Anticovid:
An open access platform for global clinical trials for SARS-CoV 2 (the virus responsible for COVID-19)

This chart exhibits trial registration in the SARS-CoV-2 landscape. In general, trial registration is affected by many biases and the case of SARS-CoV-2 certainly makes no exception. Perhaps, there is even more bias given the emergency at stake, diverting researchers from ideally registering their trials in a timely and prospective manner. In any case, chart shows a recent steep increase in clinical research activity, roughly aligned with pandemic spread. The high proportion of observational studies is quite striking, as compared to what is usually observed yet it may be explained by the critical need for “trivial” data regarding this unexpected and unknown agent.
Anticovid:
An open access platform for global clinical trials for SARS-CoV 2 (the virus responsible for COVID-19)

Trials as on Tuesday 28 April 2020

https://covid.inato.com/analysis
References & related material

PROGNOS Technology / YouTube presentations:
- Using PROGNOS: https://www.youtube.com/watch?v=jeO_UoMsApw
- Interview on PROGNOS: https://www.youtube.com/watch?v=0MKyKzTQ3pw
- Using PROGNOS on MIR by Prof. Dr. med Valeri Vladimirovich Polyakov: https://www.youtube.com/watch?v=R4hGgJShsZU

How does COVID-19 kill?
- Uncertainty is hampering doctors’ ability to choose treatments: https://www.nature.com/articles/d41586-020-01056-7

The race for coronavirus vaccines: a graphical guide - Eight ways in which scientists hope to provide immunity to SARS-CoV-2.
https://www.nature.com/articles/d41586-020-01221-y?utm_source=Nature+Briefing


COHERENCE IN LIFE AND IN MATTER - Past events and related resources (in Italian): https://www.vglobale.it/?s=Coherence

Luc Montagnier (2008 Nobel Prize in Physiology or Medicine) and Vincenzo Valenzi (an interview in Italian and French): https://youtu.be/CuQtvjBuavI

Proceedings of COHERENCE events and related material: http://www.iiimb.me/materiali.html


COVID Workshop Reports: https://m.facebook.com/story.php?story_fbid=3395611340453227&id=100000131826854
References & related material

Features of 16,749 hospitalised UK patients with COVID-19 using the ISARIC WHO Clinical Characterisation Protocol  (International Severe Acute Respiratory and emerging Infections Consortium)

Results: The median age was 72 years [IQR 57, 82; range 0, 104], the median duration of symptoms before admission was 4 days [IQR 1, 8] and the median duration of hospital stay was 7 days [IQR 4, 12]. The commonest comorbidities were chronic cardiac disease (29%), uncomplicated diabetes (19%), non-asthmatic chronic pulmonary disease (19%) and asthma (14%); 47% had no documented reported comorbidity. Increased age and comorbidities including obesity were associated with a higher probability of mortality. Distinct clusters of symptoms were found: 1. respiratory (cough, sputum, sore throat, runny nose, ear pain, wheeze, and chest pain); 2. systemic (myalgia, joint pain and fatigue); 3. enteric (abdominal pain, vomiting and diarrhoea). Overall, 49% of patients were discharged alive, 33% have died and 17% continued to receive care at date of reporting. 17% required admission to High Dependency or Intensive Care Units; of these, 31% were discharged alive, 45% died and 24% continued to receive care at the reporting date. Of those receiving mechanical ventilation, 20% were discharged alive, 53% died and 27% remained in hospital.

Conclusions: We present the largest detailed description of COVID-19 in Europe, demonstrating the importance of pandemic preparedness and the need to maintain readiness to launch research studies in response to outbreaks.

https://www.medrxiv.org/content/10.1101/2020.04.23.20076042v1.full.pdf
Features of 16,749 hospitalised UK patients with COVID-19 using the ISARIC WHO Clinical Characterisation Protocol (International Severe Acute Respiratory and emerging Infections Consortium)

Patients with outcome stratified by age, and sex

Males
4413/7346 (60%)

Females
2933/7346 (40%)

https://www.medrxiv.org/content/10.1101/2020.04.23.20076042v1.full.pdf
Features of 16,749 hospitalised UK patients with COVID-19 using the ISARIC WHO Clinical Characterisation Protocol

![Bar chart showing comorbidity distribution for patients with COVID-19.](https://www.medrxiv.org/content/10.1101/2020.04.23.20076042v1.full.pdf)
**4th MERIDIANTECH-COVID19 Workshop**

**Bioelectrical Diagnostics & Coherent Therapy**

Controlled trials of Meridian technology-based diagnostics and diagnostics-driven precision, personalized therapy

**Thursday 30 April 15:00 CEST – Hosted by MEDPREVENT systems GmbH & Co. KG DE**

**Giulio TARRO:**


Urgent need for new approaches for managing the COVID-19 pandemic

**Habib DOUAGUI:**

Professor & Head, Department of Pneumo-allergology, Center Hospitalo Universitaire de Béni Messous, Algiers, Algeria

COVID-19 in Africa: The state of play and approaches to management and care

**Judu ILAVARASU:**

Division of Yoga and Physical Sciences, Swami Vivekananda Yoga Anusandhana Samsthana (SVYASA), Bangalore, India

ACUGRAPH for COVID-19 studies: Limits and challenges

**Dr. med Michael BAUER, Raimund HOFFMAN & Franziska MICHL:**

MEDPREVENT systems GmbH, Marktredwitz, Germany

COVID-19 diagnostics and viral testing and assessment of organ health using the PROGNOS system

**Dr. med. Thomas RAMPP:**

Faculty of Medicine, University of Duisburg-Essen & Institute for Naturopathy, Traditional Chinese and Indian Medicine, Kliniken Essen-Mitte, Essen, Germany

Visco Dendron: PROGNO-based diagnostics-driven personalised selection of ‘coherent’ plant preparations for therapy

**Svetlana von GRATOWSKI:**

LABORATORY OF SPECTROSCOPY AND MILLIMETER AND SUBMILLIMETER WAVE MEASUREMENTS, Kotelnikov Institute of Radioengineering and Electronics, Russian Academy of Sciences. Fryazino Branch

Millimeter and submillimeter waves in medicine and their effects on complex biological systems
3rd MERIDIANTECH-COVID19 Workshop

Bioelectrical Diagnostics & Coherent Therapy

“Unpacking” & Understanding Meridians: Practical Measurement and Interpreting Results

Friday 23 April 18:00 CET – Hosted by MEDPREVENT systems GmbH & Co. KG DE

Raimund HOFFMAN: CEO, MEDPREVENT systems GmbH & Co. KG DE
INTRODUCTION: Review and progress with MERIDIANTECH-PROGNOSNET engagements

Judu ILAVARASU: Division of Yoga and Physical Sciences, Swami Vivekananda Yoga Anusandhana Samsthan (SVYASA), Bangalore, India: ACUGRAPH studies in SVYASA, Bangalore, India.

Dr. med Michael BAUER, Raimund HOFFMAN & Franziska MICHL: MEDPREVENTsystems GmbH
PROGNOS: The instrument, using the instrument, data structure, data analysis, results and interpretation


Alexander TROFIMOV MD: Director, International Scientific Research Institute of Cosmic Anthropoecology (ISRICA), Russia & Chief of Laboratory Helioclimatopathology of Science Center of Clinical and Experimental Medicine of Siberian Department of Russian Academy of Medical Science: Cosmicco Radiations, Solar activity and its effects on BIOLOGICAL system and and links to bacteria and viral infection susceptibility?

Madan THANGAVELU & Vincenzo VALENZI: www.iiimb.me
COVID-19: Challenges and opportunities for Pharmacogenomics, Pharmacoelectrodynamics & MERIDIANTech
2nd MERIDIANTECH-COVID19 Workshop

Bioelectrical Diagnostics & Coherent Therapy
A new bridge between Oriental and Occidental Medicine

Saturday 15 April 15:00 CET – Hosted by MEDPREVENT systems GmbH & Co. KG DE

Raimund HOFFMAN: CEO, MEDPREVENT systems GmbH & Co. KG DE

INTRODUCTION: Why I invest all my energy and money in PROGNOS technology.

Dr. med Michael BAUER, Dr med dent. Louis NIESTEGGE & Dr. med Beate MAUL (MD):
Clinical cases studied using the PROGNOS system

Antonio ACETI Professore Ordinario, Sapienza University of Rome | La Sapienza
The Rome experience with COVID-19 and possible new therapeutic strategies

Giulio TARRO: Chairman, Virosphere Biotechnology Committee, World Academy of Biomedical Technologies (WABT)–UNESCO, Paris The STRATEGY for tackling COVID19 using lessons of the past

Konstantin APYKHTIN PhD: Institute of Gerontology, National Academy of Medical Sciences of Ukraine
Mini-ECG and HRV in home monitoring of COVID 19 patients

Madan THANGAVELU & Vincenzo VALENZI: www.iiimb.me
COVID-19: Challenges and opportunities for Pharmacogenomics, Pharmacoelectrodynamics & MERIDIANTech
1st PROGOSNET-COVID19 Workshop

Functional Diagnostics & Coherent Therapy
Coherent Drugs, Compatible Foods, Nutrition & Environment

Monday 13 April 16:00 – Hosted by MEDPREVENT systems GmbH & Co. KG

Raimund HOFFMAN: Introduction to MEDPREVENT & PROGNOS

Madan THANGAVELU: COVID-19 and the complex physiological responses of a viral infection

Vincenzo VALENZI: Order and 'coherence' in complex systems and the immune system

Dr. med Michael BAUER: Clinical case studies using the PROGNOS system

Jamal AISSA, DIGIBIO, Paris: Low doses and high dilutions results of Benveniste and Montagnier and implications for COVID-19 management

Francesco SICURELLO: Telemedicine systems and opportunities for the future

Prof. Antonio ACETI: Experiences and lessons from COVID-19 critical care and management in Rome

... others to join
First they ignore you, then they laugh at you, then they fight you, then you win.

Mahatma Gandhi